Connect with us

Eyecare

$93M Raised for Dry Eye Drug Development

It will ‘bring us a step closer to offering much needed relief’ to patients.

mm

Published

on

PRINCETON, NJ — Oyster Point Pharma Inc., a pharmaceutical company developing therapies for dry eye disease, has raised $93 million in funding.

The Series B financing round was co-led by Invus Opportunities and Flying L Partners in collaboration with Falcon Vision. Existing investors New Enterprise Associates and Versant Ventures, as well as new investor Vida Ventures, participated in the round.

Eyecare Shenanigans: 2023’s Top Optometry Articles in Invision Magazine
Eyecare Shenanigans

Eyecare Shenanigans: 2023’s Top Optometry Articles in Invision Magazine

Bringing Independent ECPs Into the 21st Century With the Technology Solutions a Modern Eyecare Business Needs
INVISION Podcast

Bringing Independent ECPs Into the 21st Century With the Technology Solutions a Modern Eyecare Business Needs

The Making of Bespoke Eyewear, An Acetate Kitchen and Collecting Famous People’s Heads
INVISION Podcast

The Making of Bespoke Eyewear, An Acetate Kitchen and Collecting Famous People’s Heads

“Our team sees immense promise in this investment given Oyster Point’s encouraging clinical evidence, the potential market size, and the leadership team’s extensive experience developing and commercializing ophthalmology therapies,” said Benjamin Tsai of Invus Opportunities. “We believe Oyster Point’s therapies will redefine the standard of care for Dry Eye Disease, a condition that affects millions of people.”

Oyster Point will use the proceeds to support the development of its product portfolio for dry eye disease, explore new treatment areas and add key talent. The company’s lead product candidates, known as OC-01 and OC-02, “are delivered via an ocular surface-sparing nasal spray designed to stimulate the trigeminal parasympathetic pathway to promote natural tear film production,” according to a press release.

“In Phase 2b clinical studies, patients administered either OC-01 or OC-02 experienced rapid and significant improvements in both the signs and symptoms of Dry Eye Disease,” according to the release. “Both were well-tolerated with no significant ocular adverse events or drug-related serious adverse events.”

“Having spent decades leading and investing in ophthalmology companies, it’s exciting to see continued innovation and leadership in this space, especially in an area of such high unmet need as Dry Eye Disease,” said William Link of Flying L Partners. “We look forward to supporting the team at Oyster Point as they progress into Phase 3 clinical development, plan for commercialization, and advance additional pipeline assets.”

Advertisement

Jeffrey Nau, president and CEO of Oyster Point, said, “We are grateful to our investors for their partnership and look forward to initiating a Phase 3 clinical development program for Dry Eye Disease. Our novel approach to empower patients with Dry Eye Disease to stimulate their own natural tears has tremendous potential. This financing will bring us a step closer to offering much needed relief to patients in an area that has limited treatment options.”

SPONSORED VIDEO

SPONSORED BY VARILUX

The Best Overall Progressive Lens, Now Powered by AI

Engineered with Behavioral Artificial Intelligence and utilizing new XR-motion™ technology, Varilux XR series goes beyond prescription and eye physiology to consider the patient’s visual behavior and design a progressive lens that respects how
their eyes naturally move.

Varilux XR series comes in two versions, Varilux® XR design and Varilux® XR track. The Varilux XR track lens provides an additional level of personalization by incorporating the exclusive Near Vision Behavior Measurement, providing up to 25% more near vision width3 according to the patient’s need, so patients get the highest level of customization.

Discover Varilux XR series and enjoy instantly sharp vision in motion4 and seamless transitions from near to far.

For more information, visit here.

Promoted Headlines

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Advertisement

Most Popular